{
    "clinical_study": {
        "@rank": "166452", 
        "brief_summary": {
            "textblock": "The scientific use of basal insulin is of great help to individuals and the government.\n      However, there are few studies to investigate the real world use, effect, safety and\n      influence factors of basal insulin in China. This study is to evaluate the use of first\n      basal insulin in China patients with type 2 diabetes with inadequate glycemic control on\n      oral antidiabetic agents (OADs) from the naturalistic clinical practice."
        }, 
        "brief_title": "Observational Registry for Basal Insulin Treatment Study (ORBIT)", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Diabetes", 
        "condition_browse": {
            "mesh_term": "Diabetes Mellitus"
        }, 
        "detailed_description": {
            "textblock": "This is a 6-month multicentre, observational, prospective, registry study. About 200\n      hospitals from different parts of China will take part in this study, and about 20,000\n      patients with type 2 diabetes mellitus (T2DM) who are inadequately controlled with OADs and\n      willing to accept basal insulin (BI) treatment will be consecutively enrolled during a 12\n      months period.\n\n      The study participants will include at baseline (0 month), 3 month and end point (6 month)\n      to collect the study information. The project will probably last for about 18 months."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  18-80 years old\n\n          -  Type 2 diabetic patients\n\n          -  Taking OADs before inclusion\n\n          -  Recently tested HbA1c >=7% at the same site within 3 months\n\n          -  Being suggested by physician to start basal insulin (BI) treatment\n\n          -  Willing to start and having been prescribed BI treatment\n\n          -  Willing to join the registry study and sign the informed consent\n\n        Exclusion Criteria:\n\n          -  Diagnosed with type 1 diabetes\n\n          -  Received any type of insulin in the last 2 years (except for the intermittent use of\n             insulin of less than 1 month each time)\n\n          -  With any severe health problem, or any other situation judged by the investigator,\n             that is difficult for the 6 months follow-up\n\n          -  Current or planned pregnant, lactating women\n\n          -  Involved in other clinical trial simultaneously or at most 1 month before"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients meet the following criteria, either from in-patient or out-patient department,\n        will have chance to be enrolled in this study."
            }
        }, 
        "enrollment": {
            "#text": "20000", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 13, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01859598", 
            "org_study_id": "ORBIT"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Insulin", 
                "Hypoglycemic Agents"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "diabetes", 
            "basal insulin", 
            "effectiveness and safety", 
            "oral antidiabetic drugs", 
            "real world clinical practice"
        ], 
        "lastchanged_date": "May 20, 2013", 
        "location": [
            {
                "contact": {
                    "last_name": "Linong Ji", 
                    "phone": "+86-10-66515716"
                }, 
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "state": "Beijing"
                    }, 
                    "name": "Peking University People's Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Wei Huang", 
                    "phone": "+86-10-82619999"
                }, 
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "state": "Beijing"
                    }, 
                    "name": "Haidian hospital"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_groups": "1", 
        "official_title": "A Prospective, Observational Registry Study Focusing on the Real World Use, Effectiveness and Safety of Initial Basal Insulin Regimen in Type 2 Diabetic Patients Uncontrolled by Oral Antidiabetic Drugs in China", 
        "overall_contact": {
            "email": "zpuhong@georgeinstitute.org.cn", 
            "last_name": "Puhong Zhang, PhD", 
            "phone": "+86 10 8280 0476-512"
        }, 
        "overall_contact_backup": {
            "last_name": "Yangfeng Wu", 
            "phone": "+86 10 8280 0577"
        }, 
        "overall_official": {
            "affiliation": "The George Institute for Global Health, China", 
            "last_name": "Linong Ji, Prof.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Change of HbA1c from baseline to the end-point (6 month).\nPercentage of patients reaching the target of HbA1c <7.0% at the end-point.", 
                "measure": "To assess the change in HbA1c during the 6 months follow-up.", 
                "safety_issue": "No", 
                "time_frame": "6 month"
            }, 
            {
                "description": "The number of severe adverse events during the 6 months follow-up.\nChange of cumulative number of severe hypoglycaemic episodes during 3 months before baseline and the end-point.\nChange of cumulative number of hypoglycaemic episodes during 1 month before baseline and the end-point.\nChange of body weight from baseline to the end-point.", 
                "measure": "To assess the change in frequency of hypoglycemia and other adverse events during the 6 months follow-up.", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01859598"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Compare the HbA1c change and HbA1c control rate among the three commonly used basal insulins.", 
                "measure": "Compare the HbA1c change during the follow-up among the commonly used basal insulins (NPH, Glargine and Detemir insulin)", 
                "safety_issue": "No", 
                "time_frame": "6 month"
            }, 
            {
                "description": "Compare the following indicators among the three commonly used basal insulins:\nThe number of severe adverse events during the 6 months follow-up.\nChange of cumulative number of severe hypoglycaemic episodes during 3 months before baseline and the end-point.\nChange of cumulative number of hypoglycaemic episodes during 1 month before baseline and the end-point.\nChange of body weight from baseline to the end-point.", 
                "measure": "Compare the incidence of adverse events during the follow-up among the commonly used basal insulins (NPH, Glargine and Detemir insulin)", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }, 
            {
                "description": "To explore the influence factors of HbA1c control and adverse events by univariate and multivariate analysis.\nDependent variables: change in HbA1c, hypoglycemia and body weight\nIndependent/categorical variables: regions, level of hospital, glycemic level at baseline, type of basal insulin at baseline, dose of insulin at the endpoint, combination therapy, self monitoring of blood glucose, lifestyle, cost of drug, etc\nCovariates: demographic characteristic", 
                "measure": "To explore the factors that influence the glycemic control and safety of basal insulin regimens", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }, 
            {
                "description": "To describe and compare the change in quality of life before and after initial basal insulin regimens", 
                "measure": "To explore the impact of BI regimens to the quality of life", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }
        ], 
        "source": "The George Institute for Global Health, China", 
        "sponsors": {
            "collaborator": {
                "agency": "Chinese Diabetes Society", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "The George Institute for Global Health, China", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2011", 
        "study_design": "Observational Model: Case-Only, Time Perspective: Prospective", 
        "study_type": "Observational [Patient Registry]", 
        "target_duration": "6 Months", 
        "verification_date": "May 2013"
    }
}